Drugs / CKD-702
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04667975 | May 2020 → Aug 2021 | non-small cell lung carcinoma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05750290 | Dec 2022 → Dec 2024 | gastric cancer | National Cancer Center, Korea | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-09-13 | Chong Kun Dang Pharmaceutical | Results 종근당, 유럽종양학회에서 바이오 신약 ‘CKD-702’ 임상1상 결과 발표 ckdpharm.com ↗
임상 1 상 결과 CKD-702 의 모든 투여군에서 용량제한독성 (Dose Limiting Toxicity, DLT) 은 관찰되지 않았다 . |
| 2020-06-23 | Chong Kun Dang Pharmaceutical | Results 종근당, 미국암학회에서 항암 이중항체 ‘CKD-702’ 연구결과 발표 ckdpharm.com ↗
종근당은 22 일부터 3 일간 온라인으로 진행되는 미국암학회 (AACR, American Association for Cancer Research) 연례 학술대회에서 항암 이중항체 바이오 신약 CKD-702 의 전임상 연구결과를 발표한다 . |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-13 | Chong Kun Dang Pharmaceutical | 종근당, 유럽종양학회에서 바이오 신약 ‘CKD-702’ 임상1상 결과 발표 ckdpharm.com ↗ |
| 2020-06-23 | Chong Kun Dang Pharmaceutical | 종근당, 미국암학회에서 항암 이중항체 ‘CKD-702’ 연구결과 발표 ckdpharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04667975 ↗ |
| Route | Intravenous | “CKD-702 and irinotecan will be intravenously administered every 2 weeks.” NCT05750290 ↗ |
| Target | EGFR | “targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR)” NCT05750290 ↗ |
| Target | MET | “targeting hepatocyte growth factor receptor (MET)” NCT05750290 ↗ |